Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
10 p, 667.7 KB Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX / Kaufman, J. L. (Winship Cancer Institute. Emory University) ; Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ; White, D. (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ; Benboubker, L. (Service d'Hématologie et Thérapie Cellulaire. Hôpital Bretonneau. Centre Hospitalier Régional Universitaire) ; Cook, G. (St James's Institute of Oncology. Leeds Teaching Hospitals National Health Service Trust and University of Leeds) ; Leiba, M. (Assuta Ashdod University Hospital. Faculty of Health Science Ben-Gurion University of the Negev) ; Morton, J. (Icon Cancer Care) ; Joy Ho, P. (Institute of Haematology. Royal Prince Alfred Hospital) ; Kim, K. (Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ; Takezako, N. (Department of Hematology. National Hospital Organization Disaster Medical Center of Japan) ; Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu) ; Sutherland, H. J. (Leukemia/Bone Marrow Transplant Program. University of British Columbia) ; Magen, H. (Department of Hematology Chaim Sheba Medical Center. Ramat-Gan. Sackler Faculty of Medicine. Tel Aviv University) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University Graduate School of Medical Sciences) ; Kim, J. S. (Yonsei University College of Medicine. Severance Hospital) ; Miles Prince, H. (Cabrini Hospital. Epworth HealthCare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ; Cochrane, T. (Gold Coast University Hospital and Griffiths University) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bahlis, N. J. (University of Calgary. Arnie Charbonneau Cancer Institute) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai) ; O'Rourke, L. (Janssen Research & Development) ; Trivedi, S. (Janssen Research & Development) ; Casneuf, T. (Janssen Research & Development) ; Krevvata, M. (Janssen Research & Development) ; Ukropec, J. (Janssen Global Medical Affairs) ; Kobos, R. (Janssen Research & Development) ; Avet-Loiseau, H. (Unite de Genomique du Myelome. IUC-Oncopole) ; Usmani, S. Z. (Levine Cancer Institute/Atrium Health) ; San-Miguel, J. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Universitat Autònoma de Barcelona
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. [...]
2020 - 10.1038/s41408-020-00375-2
Blood Cancer Journal, Vol. 10 Núm. 11 (january 2020) , p. 111  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.